HYLORIS PHARMACEUTICALS SA (HYL.BR) Fundamental Analysis & Valuation

EBR:HYL • BE0974363955

Current stock price

5.45 EUR
-0.17 (-3.02%)
Last:

This HYL.BR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. HYL.BR Profitability Analysis

1.1 Basic Checks

  • HYL had negative earnings in the past year.
  • HYL had a negative operating cash flow in the past year.
  • HYL had negative earnings in each of the past 5 years.
  • In the past 5 years HYL always reported negative operating cash flow.
HYL.BR Yearly Net Income VS EBIT VS OCF VS FCFHYL.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • With a Return On Assets value of -18.99%, HYL is not doing good in the industry: 74.51% of the companies in the same industry are doing better.
  • The Return On Equity of HYL (-23.92%) is worse than 72.55% of its industry peers.
Industry RankSector Rank
ROA -18.99%
ROE -23.92%
ROIC N/A
ROA(3y)-22.2%
ROA(5y)-20.89%
ROE(3y)-27.67%
ROE(5y)-25.84%
ROIC(3y)N/A
ROIC(5y)N/A
HYL.BR Yearly ROA, ROE, ROICHYL.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200

1.3 Margins

  • HYL has a better Gross Margin (94.74%) than 98.04% of its industry peers.
  • In the last couple of years the Gross Margin of HYL has grown nicely.
  • HYL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.89%
GM growth 5Y40.76%
HYL.BR Yearly Profit, Operating, Gross MarginsHYL.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. HYL.BR Health Analysis

2.1 Basic Checks

  • HYL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • HYL has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, HYL has more shares outstanding
  • HYL has a better debt/assets ratio than last year.
HYL.BR Yearly Shares OutstandingHYL.BR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
HYL.BR Yearly Total Debt VS Total AssetsHYL.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • An Altman-Z score of 9.90 indicates that HYL is not in any danger for bankruptcy at the moment.
  • HYL has a Altman-Z score of 9.90. This is amongst the best in the industry. HYL outperforms 96.08% of its industry peers.
  • HYL has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • With an excellent Debt to Equity ratio value of 0.05, HYL belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 9.9
ROIC/WACCN/A
WACC8.1%
HYL.BR Yearly LT Debt VS Equity VS FCFHYL.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

2.3 Liquidity

  • A Current Ratio of 3.89 indicates that HYL has no problem at all paying its short term obligations.
  • HYL's Current ratio of 3.89 is amongst the best of the industry. HYL outperforms 96.08% of its industry peers.
  • A Quick Ratio of 3.88 indicates that HYL has no problem at all paying its short term obligations.
  • HYL has a Quick ratio of 3.88. This is amongst the best in the industry. HYL outperforms 96.08% of its industry peers.
Industry RankSector Rank
Current Ratio 3.89
Quick Ratio 3.88
HYL.BR Yearly Current Assets VS Current LiabilitesHYL.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. HYL.BR Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 0.09% over the past year.
  • The Revenue for HYL has decreased by -14.79% in the past year. This is quite bad
  • HYL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 110.35% yearly.
EPS 1Y (TTM)0.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.65%
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y100.07%
Revenue growth 5Y110.35%
Sales Q2Q%-2.69%

3.2 Future

  • Based on estimates for the next years, HYL will show a very strong growth in Earnings Per Share. The EPS will grow by 124.54% on average per year.
  • Based on estimates for the next years, HYL will show a very strong growth in Revenue. The Revenue will grow by 110.52% on average per year.
EPS Next Y36.89%
EPS Next 2Y86.69%
EPS Next 3Y124.54%
EPS Next 5YN/A
Revenue Next Year113.66%
Revenue Next 2Y113.68%
Revenue Next 3Y110.52%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
HYL.BR Yearly Revenue VS EstimatesHYL.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
HYL.BR Yearly EPS VS EstimatesHYL.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

1

4. HYL.BR Valuation Analysis

4.1 Price/Earnings Ratio

  • HYL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HYL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HYL.BR Price Earnings VS Forward Price EarningsHYL.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HYL.BR Per share dataHYL.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • HYL's earnings are expected to grow with 124.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y86.69%
EPS Next 3Y124.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HYL.BR Dividend Analysis

5.1 Amount

  • HYL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HYL.BR Fundamentals: All Metrics, Ratios and Statistics

HYLORIS PHARMACEUTICALS SA

EBR:HYL (4/24/2026, 5:25:00 PM)

5.45

-0.17 (-3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-26
Earnings (Next)N/A
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners58.14%
Ins Owner ChangeN/A
Market Cap152.60M
Revenue(TTM)7.21M
Net Income(TTM)-6.33M
Analysts80
Price Target13.84 (153.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-38.3%
EPS NY rev (3m)-38.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.5%
Revenue NY rev (3m)-4.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21.17
P/FCF N/A
P/OCF N/A
P/B 5.76
P/tB 7.34
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.26
BVpS0.95
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -18.99%
ROE -23.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.74%
FCFM N/A
ROA(3y)-22.2%
ROA(5y)-20.89%
ROE(3y)-27.67%
ROE(5y)-25.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.89%
GM growth 5Y40.76%
F-Score2
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.44%
Cap/Sales 8.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.89
Quick Ratio 3.88
Altman-Z 9.9
F-Score2
WACC8.1%
ROIC/WACCN/A
Cap/Depr(3y)109.73%
Cap/Depr(5y)296.13%
Cap/Sales(3y)16.06%
Cap/Sales(5y)32.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.65%
EPS Next Y36.89%
EPS Next 2Y86.69%
EPS Next 3Y124.54%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y100.07%
Revenue growth 5Y110.35%
Sales Q2Q%-2.69%
Revenue Next Year113.66%
Revenue Next 2Y113.68%
Revenue Next 3Y110.52%
Revenue Next 5YN/A
EBIT growth 1Y-26.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year248.15%
EBIT Next 3Y198.25%
EBIT Next 5YN/A
FCF growth 1Y-5.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.32%
OCF growth 3YN/A
OCF growth 5YN/A

HYLORIS PHARMACEUTICALS SA / HYL.BR Fundamental Analysis FAQ

What is the fundamental rating for HYL stock?

ChartMill assigns a fundamental rating of 4 / 10 to HYL.BR.


What is the valuation status of HYLORIS PHARMACEUTICALS SA (HYL.BR) stock?

ChartMill assigns a valuation rating of 1 / 10 to HYLORIS PHARMACEUTICALS SA (HYL.BR). This can be considered as Overvalued.


What is the profitability of HYL stock?

HYLORIS PHARMACEUTICALS SA (HYL.BR) has a profitability rating of 1 / 10.


Can you provide the financial health for HYL stock?

The financial health rating of HYLORIS PHARMACEUTICALS SA (HYL.BR) is 7 / 10.